Crystallin protein aggregation (null)

Crystallin protein aggregation Overview

Crystallin protein aggregation refers to the process by which soluble crystallin proteins (primarily α-, β-, and γ-crystallins), essential for maintaining lens transparency, undergo misfolding and self-association into insoluble aggregates within the eye lens[2][3][5]. This process is a fundamental driver of cataract formation, the leading cause of blindness worldwide[2]. Aggregation is triggered by age-related or environmentally-induced (e.g., UV light, oxidation, glycation, deamidation) damage to crystallin proteins, destabilizing their structure and leading to light-scattering protein complexes[3][4][6]. Unlike most drug targets, “crystallin protein aggregation” is not a discrete protein or receptor but a pathological process involving multiple related proteins and biochemical pathways. Research focuses on understanding the molecular mechanism of this aggregation, especially of γ-crystallin, to develop therapeutics that could prevent or reverse aggregate formation and delay cataract progression[2][4]. Currently, no approved drugs specifically prevent or reverse this aggregation; lens replacement surgery remains the main treatment[2]. Caveat: “Crystallin protein aggregation” is not a unique molecule, gene, or receptor, but instead describes a pathological process involving several proteins (especially β- and γ-crystallins) in the ocular lens[2][5]. It should not be listed as a canonical druggable target, but as a disease-relevant molecular mechanism or process[2][3][4].

Mechanism of Action

Stabilization of native crystallin structure, Inhibition of aggregation pathway (for drug candidates being researched)

Biological Functions

Safety Considerations

Interacting Drugs

Associated Biomarkers